Pfizer | PFE - Assets


Pfizer reported $208.73B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Abbott USD 86.71B 2.53B Dec/2025
ALKERMES USD 2.49B 157.48M Dec/2025
Amgen USD 90.59B 445M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Bayer EUR 104.54B 331M Dec/2025
Biogen USD 29.44B 232M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Drreddys Laboratories INR 6.26B 161.9M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Medtronic USD 91.48B 139M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Pacira USD 1.26B 32.66M Dec/2025
Perrigo USD 8.54B 1.55B Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Phibro Animal Health USD 1.41B 20.03M Dec/2025
Prestige Brands USD 3.49B 52.46M Dec/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Sanofi EUR 126.81B 25.48B Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Zoetis USD 15.47B 308M Dec/2025